Evolving ADC-Directed Therapies for HER2-negative and HER2-low mBC

home / precision-medicine / evolving-adc-directed-therapies-for-her2-negative-and-her2-low-mbc

Medical oncologists specializing in breast cancer have a comprehensive discussion on the evolving treatment landscapes for HER2-negative and HER2-low metastatic breast cancer, focusing on ADC-directed therapies.

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 1: Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer

Aditya Bardia, MD, MPH;Laura Huppert, MD

June 21st 2024

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.

Watch

EP. 2: DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer

Aditya Bardia, MD, MPH;Laura Huppert, MD

June 21st 2024

Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.

Watch

EP. 3: Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer

Aditya Bardia, MD, MPH;Laura Huppert, MD

June 27th 2024

Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.

Watch

EP. 4: Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer

Aditya Bardia, MD, MPH;Laura Huppert, MD

June 27th 2024

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.

Watch